Sends email in progress
 
Register
Login
Password
Top news
Scientific news
Advantage of next generation sequencing (NGS) over conventional sequencing (Sanger) for the detection of BCR-ABL mutations in CML patients with failure and warning after 1st - and 2nd-line treatment with a tyrosine kinase inhibitor
Leukemia
Report
Published online: 6 December 2015
Advantage of next generation sequencing (NGS) over conventional sequencing...
Pr Claude Preudhomme (CHRU de Lille)
The objective of this study was to compare 2 sequencing techniques (Sanger and NGS) for the detection of BCR-ABL mutations for patients with failure and warning to 1st- or 2nd-line tyrosine kinase inhibitor (TKI) therapy according to the 2013 ELN criteria.
Between May 2013 and June 2015, 298 patients met these criteria,...
Read more
In CML, the OPTIM-Imatinib study shows that dose adjustment of imatinib by drug monitoring improves the molecular response rate
Leukemia
Report
Published online: 5 December 2015
In CML, the OPTIM-Imatinib study shows that dose adjustment of imatinib by drug...
Dr Philippe Quittet (Hôpital Lapeyronie - CHU de Montpellier)
This study by the French CML group shows the importance of personalised treatment in CML patients in chronic phase (CML-CP) treated with first-line  imatinib (IM). This standard treatment is administered as a single dose 400 mg/d. An analysis of the IRIS study showed that the minimum serum rate (C) min> 1000 ng/mL was...
Read more
CD93 - a new leukaemia stem cell marker in chronic myeloid leukemia
Leukemia
Report
Published online: 5 December 2015
CD93 - a new leukaemia stem cell marker in chronic myeloid leukemia
Pr Claude Preudhomme (CHRU de Lille)
Although tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukaemia (CML), only a small number of patients will completely inhibit their BCR-ABL transcript, probably due to the persistence of leukaemia stem cells (LSC).
Thanks to a microarrays approach comparing CML LSCs to SCs of...
Read more
All scientific articles